Lynzol-JR Orally Disintegrating Tablet contains Lansoprazole 15 mg, a proton pump inhibitor indicated for the treatment of acid-related gastrointestinal conditions. Lansoprazole acts by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing gastric acid secretion. This formulation is designed for rapid disintegration in the oral cavity, facilitating ease of administration without the need for water, making it particularly suitable for pediatric patients or individuals with swallowing difficulties. Lynzol-JR is primarily prescribed for the management of gastroesophageal reflux disease (GERD), erosive esophagitis, and duodenal ulcers, as well as for the eradication of Helicobacter pylori infection when used in combination with appropriate antibiotics. The 15 mg dose is generally recommended for pediatric use or for patients requiring lower doses. The onset of action typically occurs within one hour, providing symptomatic relief from heartburn, acid regurgitation, and related discomfort. Patients should adhere to prescribed dosing schedules and consult healthcare professionals before use, especially if pregnant, lactating, or taking concomitant medications, to avoid potential drug interactions or adverse effects. Lynzol-JR is well tolerated, with minimal side effects reported, including headache, abdominal pain, and diarrhea.